Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. The company provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium, cisatracurium, fulvestrant, doxercalciferol, milrinone lactate, fondaparinux sodium, phenylephrine, gemcitabine, levoleucovorin, carboplatin, cytarabine, bleomycin, topotecan hydrochloride, bendamustine HCL, bortezomib, clofarabine, busulfan, dactinomycin, azacitidine, mycophenolate mofetil, tigecycline, glycopyrrolate, melphalan, daptomycin, decitabine, haloperidol decanoate, carmustine, bivalirudin, dexmedetomidine, and neostigmine methylsulfate injections. It also offers isosulfan blue, succinylcholine chloride, furosemide, regadenoson, voriconazole, ganirelix acetate, eptifibatide, enoxaparin sodium, mitomycin, vancomycin, micafungin sodium, docetaxel, nelarabine, pemetrexed, rocuronium bromide, zoledronic acid, thiamine, fluorouracil, perixafor, thiotepa, pantoprazole sodium, glatiramer acetate, and bupivacaine hydrochloride injections. The company was founded in 2000 and is based in Nanjing, China.
Metrics to compare | 603707 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship603707PeersSector | |
---|---|---|---|---|
P/E Ratio | 25.4x | 25.8x | −0.5x | |
PEG Ratio | 0.08 | −0.68 | 0.00 | |
Price/Book | 2.8x | 2.5x | 2.6x | |
Price / LTM Sales | 4.9x | 3.2x | 3.2x | |
Upside (Analyst Target) | 30.1% | 4.4% | 41.6% | |
Fair Value Upside | Unlock | 11.3% | 6.0% | Unlock |